Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-tumor compositions comprising rare ginsenoside Rk2, CK and PPT

A technology of ginsenosides and anti-tumor drugs, applied in the field of biomedicine, can solve the problems of not showing particularly significant anti-tumor effects and the like

Active Publication Date: 2020-06-12
SHAANXI GIANT BIOTECHNOLOGY CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, a large number of literatures have shown that rare ginsenoside monomers exhibit obvious anti-tumor effects, which can block the distribution of tumor cell cycle, induce tumor cell apoptosis, and inhibit tumor angiogenesis, etc., but the existing single rare ginsenoside Saponin monomers, such as the above-mentioned dozen or so rare ginsenoside monomers, did not show particularly significant antitumor effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor compositions comprising rare ginsenoside Rk2, CK and PPT
  • Anti-tumor compositions comprising rare ginsenoside Rk2, CK and PPT
  • Anti-tumor compositions comprising rare ginsenoside Rk2, CK and PPT

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1 Inhibitory effect of the rare ginsenoside Rk2 / CK / PPT composition on the proliferation of three different tumor cells

[0080] Appropriate amounts of ginsenoside Rk2, ginsenoside CK and ginsenoside PPT were weighed respectively to prepare aqueous solutions with a final concentration of 100 μg / mL, which were called Rk2, CK, and PPT in sequence. Mix ginsenoside Rk2, ginsenoside CK and ginsenoside PPT according to the weight ratio of 1:1:1, 1:1.5:1.5, 1:2:2, 1:0.5:0.5, 1:3:3 respectively, and prepare The aqueous solutions containing ginsenoside Rk2, ginsenoside CK and ginsenoside PPT with a final concentration of 100 μg / mL are referred to as composition 1, composition 2, composition 3, composition 4 and composition 5 in sequence. Mix ginsenoside Rk2 and ginsenoside CK according to the ratio of 1:1, 1:0.5, and 1:3 by weight, prepare an aqueous solution containing ginsenoside Rk2 and ginsenoside CK with a final concentration of 100 μg / mL, and call it a composition ...

Embodiment 2

[0105] Example 2 Effects of Rare Ginsenoside Rk2 / CK / PPT Composition 1, Composition 6, Composition 9 and Composition 12 on the Cycle Distribution of Colon Cancer Cells

[0106] Inoculate colon cancer cells in a sterile 6-well plate, and after culturing for 24 hours, add ginsenoside Rk2, ginsenoside CK, ginsenoside PPT, composition 1, composition 6, composition 9 and composition 12. An equal volume of RPMI-1640 culture solution was added to the control group, and 5 replicate wells were set for each concentration. After continuing to culture for 48 hours, add ice-cold PBS to wash 2-3 times, add 75% ice ethanol, adjust the cells to a suitable density and place them in a 4°C refrigerator overnight. Then add ice-cold PBS to wash 2-3 times, add an appropriate amount of PI solution dropwise, and incubate in the dark for 30 minutes, and use flow cytometry to detect the distribution of cell cycle.

[0107] figure 1 It is a graph showing the experimental results of detecting the effec...

Embodiment 3

[0111] Example 3 Effects of Rare Ginsenoside Rk2 / CK / PPT Composition 1, Composition 6, Composition 9 and Composition 12 on Inducing Apoptosis of Colon Cancer Cells

[0112] Inoculate colon cancer cells in a sterile 6-well plate, and after culturing for 24 hours, add ginsenoside Rk2, ginsenoside CK, ginsenoside PPT, composition 1, composition 6, composition 9 and composition 12. An equal volume of RPMI-1640 culture solution was added to the control group, and 5 replicate wells were set for each concentration. After continuing to culture for 48 hours, add ice-cold PBS to wash 2-3 times, add 1×Binding Buffer buffer, pipette evenly, drop an appropriate amount of AV / PI mixed dye solution, incubate in the dark for 15 minutes, and use flow cytometry to detect cell apoptosis. and calculate the combination index CI of the two drugs of the composition:

[0113] CI=(1-A×B) / (1-AB)

[0114]Where T is the cell survival fraction of the experimental group, C is the cell survival fraction of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an anti-tumor composition comprising rare ginsenosides Rk2, CK and PPT. The anti-tumor composition of the present invention comprises a therapeutically effective amountof ginsenoside Rk2, ginsenoside CK and ginsenoside PPT as active ingredients, and a pharmaceutically acceptable carrier, the rare ginsenoside pharmaceutical composition comprises ginsenoside Rk2, ginsenoside CK and ginsenoside PPT in a weight ratio of 1: (1-2): (1-2). Under the condition that the weight ratio of the ginsenoside Rk2 to the ginsenoside CK to the ginsenoside PPT is a specific ratio,in the anti-tumor composition, the ginsenoside Rk2, the ginsenoside CK and the ginsenoside PPT have a synergistic effect, and any two of the ginsenoside Rk2, the ginsenoside CK and the ginsenoside PPTalso have a synergistic effect.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a synergistic rare ginsenoside Rk2 / CK / PPT composition with anti-tumor activity. Background technique [0002] As one of the most serious and malignant diseases in the world, cancer has seriously threatened human health and quality of life. Its morbidity and mortality are second only to cardiovascular and cerebrovascular diseases, and it is one of the most important factors of human death. one. The incidence of cancer in the country is severe, and the incidence and mortality of different cancers such as lung cancer, breast cancer, and colon cancer continue to rise. There are about 4 million new cancer cases and about 2.5 million cancer deaths every year. At present, chemotherapy, radiation therapy and surgical treatment are more popular treatment methods for cancer. Although these traditional treatment methods can alleviate the disease, they have serious side effects and bring great ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00
CPCA61K31/704A61P35/00A61K2300/00
Inventor 范代娣董杨芳段志广马晓轩
Owner SHAANXI GIANT BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com